This invention is directed to methods for manipulating sex, reversing sex, changing sex ratio, or moderating crustacean androgenic gland peptide expression in crustaceans for producing a monosex culture. In one embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a male crustacean. In another embodiment, the present method comprises the step of injecting a dsRNA for the gene of IAG into a female crustacean that had acquired a spermatophore (a sperm sac) after mating with a male. In another embodiment, the present invention provides a method of producing a monosex culture of crustacean by introducing a recombinant IAG peptide into the female crustacean, thereby obtains male with altered sexual characteristics for mating with a normal female. In one embodiment, the crustacean is a shrimp or lobster.

Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.

Provided herein are methods of sterilizing fish by contacting an embryonic or juvenile fish with a compound of formula (I). In some embodiments, the compound is primordazine or a derivative thereof.

An object of the present invention is to produce sterilized male individuals of marine fish. Another object of the present invention is to provide a method for preventing reproduction using the sterilized male individuals. The objects are achieved by using a method for producing the sterilized male individuals of marine fish, the method including: suppressing functional expression of at least one selected from a follicle-stimulating hormone receptor (FSHR) and a ligand thereof.

The present disclosure relates to methods for inducing intracranial tumor in a non-human animal. The disclosure also relates to an intracranial cancer engineered non-human animal model with a combination of viral vectors encoding oncogenes or shRNA targeting tumor suppressor genes and a population of intracranial cancer cells derived therefrom.

Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.

Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.

Methods and compositions are provided for generating antigen-binding proteins against a foreign antigen of interest.

This disclosure is based, in part, on the unexpected discovery that a piRNA-based construct is able to silence genes that are essential for transmission and/or infection of pathogens. The disclosed constructs and methods of use thereof capitalize on the role piRNAs play in transcriptional silencing and general immunity and enable development of transgenic approaches to inhibit transmission of human and crop diseases.

Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyocytes, and tumors.